Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect: 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval 30-40% of marketplace plans to add coverage within 12 months Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion) Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications)
Thus, icodec pharmacokinetics are not affected by combining icodec with semaglutide in IcoSema
At Melamed Weight & Wellness in Deerfield, were thrilled about retatrutide a cutting-edge weight loss and anti-inflammatory peptide therapy thats generating buzz in Chicago and the North Shore
Is it really a miracle cure? Lebsack also interviewed McGills Jarry, who wrote an article in late 2023 well ahead of a rush of related online articles called The human lab rats injecting themselves with peptides. Jarry discussed the hard science, and lack thereof, of many popular stacks, as recapped below
